NCT02354612

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Tracon Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label, continuation study

Detailed description

This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	TRC105
DRUG	Bevacizumab	companion therapy selection depends on companion therapy used in the parent study
DRUG	Axitinib	companion therapy selection depends on companion therapy used in the parent study
DRUG	Pazopanib	companion therapy selection depends on companion therapy used in the parent study
DRUG	Capecitabine	companion therapy selection depends on companion therapy used in the parent study

Timeline

• First posted: 2015-02-03
• Last updated: 2021-02-15

Locations

1 site across 1 country: United States